Meta AnalysisID 2754
石杉碱甲治疗精神分裂症认知缺陷：一项系统评价和Meta分析
CRD42015024198
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Huperzine A in the treatment of schizophrenia or related disorders (schizoaffective-, schizophreniform-, or delusion
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2754
- Evidence Id
- 11312
- Core Evidence Id
- 11312
- Source Meta Analysis Id
- 2708
- Herb2 Meta Analysis Id
- HBMA002708
- Crd Id
- CRD42015024198
- Title
- Huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Huperzine A in the treatment of schizophrenia or related disorders (schizoaffective-, schizophreniform-, or delusional disorder, any diagnostic criteria)
- Study Type Included
- Only randomised controlled trials will be included.
- Condition Being Studied
- Huperzine A, an alkaloid initially identified from the Chinese herbal medicine Huperia serrata, is a potent reversible acetylcholinesterase (AChE) inhibitor and has been shown to have cognition-enhancing effects in animal models and patients with Alzheimer's disease. So we will evaluate the efficacy and safety of adjunctive Huperzine A vs placebo in the treatment of schizophrenia or related disorders (schizoaffective-, schizophreniform-, or delusional disorder, any diagnostic criteria). There were no restrictions regarding language, sample size, or time period.
- Participant
- Patients using antipsychotic drugs.
- Animal
- Human Disease Modelled
- Intervention
- Huperzine A plus antipsychotic drugs.
- Comparator Control
- Antipsychotic drugs plus placebo or antipsychotic drugs monotherapy
- Main Outcome
- Cognitive effect assessed by any instrument.
- Outcome Measure
- Additional Outcome
- 1) Changes in scores of Positive and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale Total (BPRS) total score from baseline to end of treatment. 2) Adverse events. 3) Discontinuation.
- Study Method
- Keyword
- Alkaloids; Cognition; Humans; Mental Disorders; Schizophrenia; Sesquiterpenes
- Contact
- Dr Zheng [email protected]
- Organisational Affiliation
- Guangzhou Brain Hospital (Guangzhou Huiai Hospital), Affiliated Hospital of Guangzhou Medical University
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Completed published
- First Submission Date
- Registration Date
- 2015-07-06
- Anticipated Start Date
- 2015-02-01
- Anticipated Completion Date
- 2016-09-23
- Title Cn
- 石杉碱甲治疗精神分裂症认知缺陷：一项系统评价和Meta分析
- Title En
- Huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis
- Bilingual Status
- complete